We present a theoretical framework that enables us to dissect out the parametric dependencies of the pathogenesis of prion diseases. We are able to determine the influence of both hostdependent factors (connectivity, cell density, protein synthesis rate, and cell death) and strain-dependent factors (cell tropism, virulence, and replication rate). We use a model based on a linked system of differential equations on a lattice to explore how the regional distribution of central nervous system pathology in Creutzfeldt-Jakob disease, Gerstmann-Strä ussler-Scheinker syndrome, and fatal familial insomnia relates to each of these factors. The model then is used to make qualitative predictions about the pathology for two possible hypothetical triggers of neuronal loss in prion diseases. Pathological progression in overexpressing mouse models has been shown to depend on the site of initial infection. The model allows us to compare the pathologies resulting from different inoculation routes.
. The presence of PrP Sc within nervous tissue results in the formation of amyloid plaques, spongiform changes, reactive astrocytosis, and neuronal loss (3) (4) (5) . A characteristic feature of these diseases is the large degree of variation in the distribution and magnitude of pathological changes associated both with the host species and the PrP Sc strain (6, 7) . These variations have been attributed to several factors including the kinetics of prion propagation, cell tropism, differential toxicity, and host neuro-anatomy and genetic makeup. In experimental systems it is difficult to separate these diverse causes and thereby determine the impact of each variable independently. In the present study we develop a model for prion propagation within the central nervous system, which allows us to explore each of the parameters involved in prion pathogenesis.
All of the known prion diseases in animals and humans can be correlated with an accumulation of PrP Sc in the central nervous system, suggesting that the information carrying pathogen is a protein (8) . Pronounced differences in human pathology emerge in comparisons of Creutzfeldt-Jakob disease (CJD), GerstmannSträussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI) cases (3) (4) (5) 9) . In familial CJD, loss of neurons and astrocytosis is prominent in gray matter, and PrP amyloid plaques sometimes are reported. These plaques tend to be found in the cerebellum adjacent to the Purkinje cells and sometimes are arranged in arrays. In new variant CJD numerous kuru-type PrP plaques are observed surrounded by a halo of spongiform degeneration. The number of plaques in CJD correlates positively with disease latency. In iatrogenic CJD, lesions and plaques are distributed more diffusely throughout the brain (3). In kuru around 70% of cases have plaques, and the number is greater in long latency cases. In GSS PrP plaques are common and have a unique multicentric configuration; in FFI no plaques have been observed. A similar spectrum of pathology is observed in the animal prion diseases (14) . The genotype of the host has an enormous influence on disease susceptibility and progression. For example, mutations at codon 129 of the human prion gene have been shown to be as important in determining pathology as the PrP isotype (11) .
Methods
This paper differs from previous theoretical work on prion infection (12) (13) (14) (15) (16) as it focuses on pathogenesis in the brain. This approach allows us to explore mechanisms giving rise to variations in the neuropathology. We start with a description of PrP Sc replication kinetics. Throughout we assume that PrP Sc is required for the transformation of PrP c , thus we subscribe to a protein-only transmission mechanism. This mechanism has been suggested to involve either some form of nucleationdependent aggregation (15) or a conformational change of the PrP (1). In both cases one describes the metabolic pathways by which the diseased form of the protein is formed from the healthy PrP c and how it is then incorporated into ␤-amyloid. We model this process qualitatively and use a generic realization of the metabolic pathway:
We describe the mathematical model of the disease kinetics in detail in Appendix 1. The within-cell dynamics consist of the PrP c 3 PrP (Fig. 1a) and a higher rate of production (Fig.  1b) . After a short period (T2) infection has spread to a number of cells through bidirectional connections in Fig. 1 a and b . In Fig.  1a the concentration of PrP Sc in each cell other than at the site of the inoculum remains negligible. By contrast, the high production series (Fig. 1b) shows that each of the strongly connected cells already has accumulated considerable PrP Sc . By T3 the low turnover series (Fig. 1a) is building up PrP Sc concentration, whereas the high production series is already nearing saturation. Thus turnover significantly influences the spatial and temporal distribution of PrP Sc . The same pattern is true for the distribution of PrP-amyloid (Fig. 2) . The high turnover series (Fig. 2b) shows a much faster rate of deposition and a more abundant distribution of amyloid than the baseline infection (Fig. 2a) . (Fig. 2a) .
Inhibitory Effects of PrP
Effects of Local Neuronal Connectivity. Different regions in the central nervous system possess different numbers of connections per neuron. Within the cerebellum the average number of connections a neuron can form varies from a few dozen for granular cells to 150,000 for Purkinje cells. Therefore we will next investigate the influence of structural variation in different brain regions on the patterns of PrP Sc and amyloid deposition. In Fig. 1d we have doubled the mean connectivity in our model while keeping all other parameters fixed. Early in the infectious process we notice that more cells are involved than in the baseline infection (Fig. 1a) . By the final stages of infection PrP Sc is abundant in each cell. Thus PrP deposition is increased significantly in highly connected regions, and progression to clinical disease is expected to be more rapid in these regions. In Fig. 3 we plot the time course of neuronal loss. In the top series (Fig. 3a) we assume direct activation of apoptosis whereas in the bottom series we assume death through loss of function (Fig. 3b) . Over the first four epochs of infection degeneration is indistinguishable. This is because we are seeing the early phase of infection, during which there is transport and transformation of susceptible cells rather than cell death. By the time T5 the PrP Sc neurotoxicity series (Fig. 3a) is beginning to show signs of cell death as more of the brain degenerates. At T6 the differences between the two treatments have become very pronounced. PrP Sc accumulates rapidly within the infected cells in a densitydependent fashion, whereas PrP c depletes slowly as cells are constantly synthesizing new PrP, resulting in a delayed onset of cell loss.
The differences in PrP-amyloid deposition are more revealing. In Fig. 4 we plot the absolute amyloid concentrations for epochs T1, T5, and T10 corresponding to Thus a strain has a higher rate of transformation within cells for which it has a preferential tropism.
In Fig. 5a we have assumed that k ϭ k 0 in the front half of the lattice and k ϭ 2 ϫ k 0 in the back half (k 0 ϭ 0.0001). In Fig. 5b we have moved the site of initial inoculation. Independent of the site of inoculation, PrP Sc deposition and disease progression are more pronounced in the region with the higher value of k. If different forms of PrP c do occur in the same brain, then it is possible for small variations in the value of k associated with different strains to lead to radically different PrP Sc accumulation patterns.
Discussion
We have modeled neuropathogenesis by a spatial model incorporating the reaction kinetics of PrP c conversion to PrP Sc . Using the modeling approach we have attempted to separate out strainand host-dependent factors. In the following qualitative discussion we relate our results to empirical findings. We were only able to show characteristic cases but our study has shown remarkable robustness in all of the parameters including k, ␥, and K. Moreover we found that the results for the cell loss triggers are qualitatively the same for a wide range of threshold values. Simulations were run with up to 5,000 cells, and no qualitative difference was found for the smaller numbers presented here. The documented C-source code used for the simulations can be downloaded on our web site: http:͞͞ mathbiol.zoo.ox.ac.uk͞michael͞prions.html.
The model shows the huge influence PrP c turnover and neuronal connectivity exerts on disease progression. Axonal regression, which is observed in prion diseases (23) , on the other hand, was not found to alter the spatial dynamics of the infectious agent significantly. Loss of connectivity is, however, functionally equivalent to loss of neurons, and we therefore expect to find neurological change as axons regress.
The model shows that neuronal connectivity profoundly influences pathogenesis; it is probably the high density of neuronal connections in the cerebellum (which holds about 30% of the neurons in 10% of the total volume of the brain) that gives rise to the very similar early clinical progressions observed in the human prion diseases. This is also confirmed by neuropathology: in kuru and GSS PrP-amyloid is found at relatively high concentrations in the cerebellum. Neuronal loss is also most severe in GSS (3) (4) (5) .
As a result of the use of mice overexpressing PrP in experimental inoculation studies (9, 24) pathology often differs from naturally occurring diseases (where oral intake is presumably more common). PrP c overexpression accelerates intracellular replication dynamics and loss of neurons. This has the result that early clinical symptoms stem from neuronal degradation close to the inoculation site and not from damage to regions toward which PrP Sc is ''naturally'' attracted. To gain a better understanding of human prion disease pathogenesis it therefore seems important to use transgenic models that (i) are inoculated orally and (ii) do not overexpress human PrP c . The problem is that overexpression is required to ensure infection over a manageable time scale; but, using the modeling approach outlined above, predictions about the pathology in naturally occurring disease also can be derived from experiments with overexpressing mice.
Although the precise mechanism by which neuro-degeneration occurs remains uncertain, evidence suggests that apoptosis is responsible for neuronal death (19, 20) . The accumulation of PrP Sc could induce neurons to enter into apoptosis either through direct activation of cell death (25, 26) or through the competitive elimination of essential PrP c molecules (27) . The former explanation often has been favored as prion knockout mice exhibit few deleterious phenotypes (40). In the absence of positive, conditional knockout mice models the nature of the cell loss trigger remains currently undecided by experiments (2) .
Our model has allowed us to explore the neuropathological implications of both of these mechanisms. In the case where PrP Sc is neurotoxic, a large number of cells are induced into cell death before an appreciable quantity of PrP-amyloid has been deposited. Whereas when cell death results from PrP c depletion, cells take a longer time to die and thereby produce a much larger quantity of PrP-amyloid. Thus abundant PrP-amyloid may be symptomatic of loss of function, whereas cell loss may be symptomatic of direct activation of apoptosis. With this result in mind we can contrast the pathologies of CJD, GSS, and FFI. In CJD there is a large amount of cell death and relatively few plaques. In GSS (and also in kuru) there are numerous plaques and less cell death. We hypothesize that in CJD and in particular in FFI, PrP Sc is able to directly induce cell loss. By contrast, PrP Sc͞GSS is less toxic and hence cell death is primarily a consequence of PrP c depletion. Of course, amyloid frequency also reflects the strain and potentially the body's capability of partially digesting that particular strain.
Numerous studies have demonstrated that PrP Sc accumulation is highly strain-dependent (22) . The existence of differentially glycosylated PrP c forms in the same host brain or of different molecular chaperones in the PrP c 3 PrP Sc structural change can lead to radically different PrP Sc and PrP-amyloid accumulation patterns and lesion profiles. A recent finding is that in scrapie-infected mice, cortical parvalbumin neurons are severely reduced whereas calbindin and calretinin neurons remain unaffected (29) . In CJD-inoculated mice, loss of parvalbumin neurons is severe and occurs very early after inoculation (30) .
Although we cannot explain the mechanisms behind cellular tropism of PrP Sc with our model, we can approximate them, assuming differences in the replication rate of PrP Sc with different forms of PrP c . Thus an important result of our model has been to show how partial tropism can lead to strain-specific PrP Sc accumulation patterns. In fact, at least in our model, in a protein-only mechanism of transmissible spongiform encephalopathies cellular tropism is both necessary and sufficient to generate different pathological phenotypes.
The present work suggests a path toward an understanding of prion-related pathogenesis. We believe that by adding structural detail to the model predictions for empirically derived PrP Sc accumulation patterns after inoculation are in reach. Furthermore, the model provides a conceptual assay of the neurotoxicity of different PrP Sc isoforms in prion diseases.
Appendix 1: The Kinetic Model
We model prion propagation with the following system of ordinary differential equations: , and extracellular PrP plaques, respectively, and the index i labels the cells. PrP c is assumed to be created at a cell specific rate ␣ i and destroyed within cells at a rate ␤ i (in the absence of tropism we have ␣ i ϭ ␣ and ␤ i ϭ ␤ @i). PrP c is converted into PrP Sc upon contact at a rate kx i (t)y i (t) (15) . We assume that PrP 
